Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 86229

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Genital
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s Report, “Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Genital Herpes Report is to understand the market and pipeline status of the drugs around the Genital Herpes to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Genital Herpes. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:

• A snapshot of the global Market and Phase III therapeutics scenario for Genital Herpes.

• A review of the marketed products under prescription for Genital Herpes, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Genital Herpes with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Genital Herpes drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Genital Herpes drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Genital Herpes drugs.

• Coverage of Genital Herpes Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure to 2018.

Reasons to buy

• Evaluate the marketing status and exclusivity details of Genital Herpes key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Genital Herpes.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Genital Herpes.

• API intelligence over marketed drugs forGenital Herpesand gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III Pipeline drugs.

• Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Genital Herpes.

• Uncovering opportunities in the rapidly growing US market.

Table of Contents
for Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Genital Herpes Therapeutic Market, US, Marketed Drugs by Application Type, 2017

• Genital Herpes Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017

• Genital Herpes Therapeutic Market, US, (Year), 2017

• Genital Herpes Marketed Drugs, API Manufacturers by US DMF Status, 2017

• Genital Herpes Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Genital Herpes Drugs, API Manufacturers, Europe by Country, 2017

• Genital Herpes Drugs, API Manufacturers, India by State, 2017

• Genital Herpes Drugs, API Manufacturers, China by Province, 2017

• Genital Herpes Drugs, API Manufacturers by Geography 2017

• Genital Herpes Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Genital Herpes Therapeutic Market, Global Sales-2018 (in million USD)

• API Manufacturers for Drug, 2017

• Phase III Drugs for Genital Herpes, 2017

• Discontinued Drugs for Genital Herpes, 2017

List Of Figures, Charts and Diagrams
in Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Genital Herpes Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017

• Genital Herpes Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017

• Genital Herpes Therapeutic Market, US, (Year), 2017

• Genital Herpes Marketed Drugs, API Manufacturers by US DMF Status (%), 2017

• Genital Herpes Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Genital Herpes Drugs, API Manufacturers, Europe by Country, 2017

• Genital Herpes Drugs, API Manufacturers, India by State, 2017

• Genital Herpes Drugs, API Manufacturers, China by Province, 2017

• Genital Herpes Drugs, API Manufacturers by Geography 2017

• Genital Herpes Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Genital Herpes Therapeutic Market, Global Sales 2018 (in million USD)

• Drug, Patent/Exclusivity Expiry (Year), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

86229 | DIIR2017063

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Genital Herpes - Epidemiology Forecast To 2023
DelveInsight “Genital Herpes - Epidemiology Forecast To 2023” provides an overview of the epidemiolo...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Genital Herpes-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Genital Herpes - Market Ins...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Genital Herpes-Pipeline Insights, 2017
DelveInsight’s, “ Genital Herpes-Pipeline Insights, 2017”, report provides in depth insights on the ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017
DelveInsight’s, “ Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017”, report provides in...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Herpes - Pipeline Review, H1 2017
Genital Herpes - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and He...
22 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016
Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Global Clinical Trials Review, H1, 2016
Genital Herpes Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Ge...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Treatment Market: By Product type (Acyclovir, Famciclovir, Valacyclovir), By Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores) & Geography -Forecast (2016-2021)
General herpes is categorised as a sexually transmitted disease/infection (STI) which is caused by h...
18 Feb 2016 by USD $4,463 (normally
USD $5,251)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...